Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Guidelines for the management of hereditary ATTR amyloidosis 2026.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis·2026
Same author

Systemic light chain and transthyretin amyloidosis-treatment advancements and future directions.

Lancet (London, England)·2026
Same author

Multifaceted effects of N-glycosylation on amyloidogenic κ light chains in AL amyloidosis.

Structure (London, England : 1993)·2026
Same author

A Phase 2 trial of daratumumab monotherapy in newly diagnosed patients with cardiac stage IIIb AL amyloidosis.

Blood·2026
Same author

Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.

Blood·2026
Same author

Cardiac Biomarker Complete Response in AL Amyloidosis: Characteristics, Cardiac Recovery, and Survival of 63 Patients.

JACC. CardioOncology·2026

Related Experiment Video

Updated: Apr 24, 2026

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line
06:38

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line

Published on: August 2, 2021

30.2K

Waldenström macroglobulinemia.

Steven P Treon1, Zachary R Hunter1, Jorge J Castillo1

  • 1Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.

Hematology/Oncology Clinics of North America
|September 13, 2014
PubMed
Summary
This summary is machine-generated.

Waldenström macroglobulinemia (WM) is a B-cell disorder often linked to specific gene mutations. Understanding these mutations and signaling pathways is key to developing targeted therapies for WM patients.

Keywords:
CXCR4 WHIM mutationsLymphoproliferative disorderMYD88 L265PMorbidityTreatment optionsWaldenström macroglobulinemia

More Related Videos

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

6.8K
Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

15.5K

Related Experiment Videos

Last Updated: Apr 24, 2026

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line
06:38

Macrophage Differentiation and Polarization into an M2-Like Phenotype using a Human Monocyte-Like THP-1 Leukemia Cell Line

Published on: August 2, 2021

30.2K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

6.8K
Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

15.5K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Waldenström macroglobulinemia (WM) is an IgM-secreting B-cell lymphoproliferative disorder.
  • WM exhibits a strong familial predisposition.
  • Common mutations like MYD88 L265P and CXCR4 WHIM are crucial for WM cell growth and survival.

Purpose of the Study:

  • To summarize the current understanding of Waldenström macroglobulinemia.
  • To highlight the role of genetic mutations in WM pathogenesis.
  • To discuss current and emerging therapeutic strategies for WM.

Main Methods:

  • Review of existing literature on WM.
  • Analysis of common genetic mutations (MYD88, CXCR4) in WM.
  • Overview of current treatment modalities and their toxicities.

Main Results:

  • WM pathogenesis involves specific genetic mutations supporting tumor cell growth.
  • Clinical manifestations stem from tumor infiltration and paraprotein production.
  • Current treatments include a range of agents with varying toxicities.

Conclusions:

  • Elucidating WM signaling pathways is crucial for advancing targeted therapeutics.
  • Targeted efforts focus on MYD88 and CXCR4 signaling pathways.
  • Treatment decisions require careful consideration of short- and long-term toxicities.